Captrust Financial Advisors C4 Therapeutics, Inc. Transaction History
Captrust Financial Advisors
- $30.9 Billion
- Q2 2024
A detailed history of Captrust Financial Advisors transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 14,822 shares of CCCC stock, worth $89,821. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,822
Previous 14,822
-0.0%
Holding current value
$89,821
Previous $121,000
43.8%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CCCC
# of Institutions
129Shares Held
54MCall Options Held
331KPut Options Held
145K-
Ra Capital Management, L.P. Boston, MA4.88MShares$29.6 Million0.34% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.85MShares$29.4 Million0.12% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$27.6 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT4.05MShares$24.6 Million1.9% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.56MShares$21.6 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $296M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...